within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CH03_Tasimelteon;

model Tasimelteon
  extends Pharmacolibrary.Drugs.ATC.N.N05CH03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N05CH03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tasimelteon is a melatonin receptor agonist targeting MT1 and MT2 receptors, approved for the treatment of non-24-hour sleep-wake disorder (Non-24), primarily in totally blind adults. It is also investigated for circadian rhythm sleep disorders. The drug is currently approved and in use.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers; oral administration; single and repeated doses.</p><h4>References</h4><ol><li><p>Dhillon, S, &amp; Clarke, M (2014). Tasimelteon: first global approval. <i>Drugs</i> 74(4) 505–511. DOI:<a href=\"https://doi.org/10.1007/s40265-014-0200-1\">10.1007/s40265-014-0200-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24610704/\">https://pubmed.ncbi.nlm.nih.gov/24610704</a></p></li><li><p>Torres, R, et al., &amp; Baroldi, P (2015). Absolute Bioavailability of Tasimelteon. <i>American journal of therapeutics</i> 22(5) 355–360. DOI:<a href=\"https://doi.org/10.1097/MJT.0000000000000195\">10.1097/MJT.0000000000000195</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25658956/\">https://pubmed.ncbi.nlm.nih.gov/25658956</a></p></li><li><p>Neubauer, DN (2014). New and emerging pharmacotherapeutic approaches for insomnia. <i>International review of psychiatry (Abingdon, England)</i> 26(2) 214–224. DOI:<a href=\"https://doi.org/10.3109/09540261.2014.888990\">10.3109/09540261.2014.888990</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24892896/\">https://pubmed.ncbi.nlm.nih.gov/24892896</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Tasimelteon;
